<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" media="screen" href="/~d/styles/rss2full.xsl"?><?xml-stylesheet type="text/css" media="screen" href="http://feeds.feedburner.com/~d/styles/itemcontent.css"?><rss xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:wfw="http://wellformedweb.org/CommentAPI/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:sy="http://purl.org/rss/1.0/modules/syndication/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/" version="2.0">

<channel>
	<title>InvestorGuide.com » Stock of the Day</title>
	
	<link>http://www.investorguide.com/article</link>
	<description>Investing in YOUR financial future</description>
	<lastBuildDate>Thu, 17 Oct 2013 13:47:05 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	
		<atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="self" type="application/rss+xml" href="http://feeds.feedburner.com/InvestorguideSOD" /><feedburner:info xmlns:feedburner="http://rssnamespace.org/feedburner/ext/1.0" uri="investorguidesod" /><atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="hub" href="http://pubsubhubbub.appspot.com/" /><item>
		<title>Alnylam Pharmaceuticals’ (ALNY) New Cholesterol Treatment Could Be A Next Generation Blockbuster</title>
		<link>http://www.investorguide.com/article/14094/alnylam-pharmaceuticals-alny-new-cholesterol-treatment-could-be-a-next-generation-blockbuster-sod/</link>
		<comments>http://www.investorguide.com/article/14094/alnylam-pharmaceuticals-alny-new-cholesterol-treatment-could-be-a-next-generation-blockbuster-sod/#comments</comments>
		<pubDate>Thu, 17 Oct 2013 13:45:58 +0000</pubDate>
		<dc:creator>Leo Sun</dc:creator>
				<category><![CDATA[Stock of the Day]]></category>
		<category><![CDATA[IG Original]]></category>

		<guid isPermaLink="0">http://www.investorguide.com/article/?p=14094</guid>
		<description><![CDATA[<p>Earlier this month, Alnylam Pharmaceuticals (ALNY) impressed investors with positive results from its phase 1 study of its experimental high cholesterol drug, ALN-PCS. The results showed that ALN-PCS reduced LDL (&#8220;bad&#8221;) cholesterol by an average of 40%. Although this is an early study, it shows potential of becoming a new, more effective treatment in a<br /><a class="moretag" href="http://www.investorguide.com/article/14094/alnylam-pharmaceuticals-alny-new-cholesterol-treatment-could-be-a-next-generation-blockbuster-sod/">Read the full article...</a></p><p>Read the rest of <a href="http://www.investorguide.com/article/14094/alnylam-pharmaceuticals-alny-new-cholesterol-treatment-could-be-a-next-generation-blockbuster-sod/">Alnylam Pharmaceuticals’ (ALNY) New Cholesterol Treatment Could Be A Next Generation Blockbuster</a> at <a href="http://www.investorguide.com/article">InvestorGuide.com</a>.</p>]]></description>
		<wfw:commentRss>http://www.investorguide.com/article/14094/alnylam-pharmaceuticals-alny-new-cholesterol-treatment-could-be-a-next-generation-blockbuster-sod/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	    <image>
   http://www.investorguide.com/images/social/social-stock-1.jpg  	</image>
	</item>
		<item>
		<title>Yahoo! (YHOO) Reports Drop In Profit, Alibaba Share Amendment</title>
		<link>http://www.investorguide.com/article/14091/yahoo-yhoo-reports-drop-in-profit-alibaba-share-amendment-sod/</link>
		<comments>http://www.investorguide.com/article/14091/yahoo-yhoo-reports-drop-in-profit-alibaba-share-amendment-sod/#comments</comments>
		<pubDate>Wed, 16 Oct 2013 14:07:23 +0000</pubDate>
		<dc:creator>Jay Hawk</dc:creator>
				<category><![CDATA[Stock of the Day]]></category>
		<category><![CDATA[IG Original]]></category>

		<guid isPermaLink="0">http://www.investorguide.com/article/?p=14091</guid>
		<description><![CDATA[<p>Shares of Yahoo! Inc. (YHOO) were up +1.02 or +3.06% to $34.28 per share in pre-market trading on Wednesday after the company announced its fiscal third quarter earnings following the market close on Tuesday. Yahoo! shares were down -0.62 or -1.82% to close at $33.38 in Tuesday’s regular trading session. In a separate release, Yahoo!<br /><a class="moretag" href="http://www.investorguide.com/article/14091/yahoo-yhoo-reports-drop-in-profit-alibaba-share-amendment-sod/">Read the full article...</a></p><p>Read the rest of <a href="http://www.investorguide.com/article/14091/yahoo-yhoo-reports-drop-in-profit-alibaba-share-amendment-sod/">Yahoo! (YHOO) Reports Drop In Profit, Alibaba Share Amendment</a> at <a href="http://www.investorguide.com/article">InvestorGuide.com</a>.</p>]]></description>
		<wfw:commentRss>http://www.investorguide.com/article/14091/yahoo-yhoo-reports-drop-in-profit-alibaba-share-amendment-sod/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	    <image>
   http://www.investorguide.com/images/social/social-stock-3.jpg  	</image>
	</item>
		<item>
		<title>Achillion Pharmaceuticals (ACHN) Gets Wiped Out After FDA Maintains Hold On Its Lead Drug</title>
		<link>http://www.investorguide.com/article/14088/achillion-pharmaceuticals-achn-gets-wiped-out-after-fda-maintains-hold-on-its-lead-drug-sod/</link>
		<comments>http://www.investorguide.com/article/14088/achillion-pharmaceuticals-achn-gets-wiped-out-after-fda-maintains-hold-on-its-lead-drug-sod/#comments</comments>
		<pubDate>Tue, 15 Oct 2013 14:02:39 +0000</pubDate>
		<dc:creator>Leo Sun</dc:creator>
				<category><![CDATA[Stock of the Day]]></category>
		<category><![CDATA[IG Original]]></category>

		<guid isPermaLink="0">http://www.investorguide.com/article/?p=14088</guid>
		<description><![CDATA[<p>Shares of Achillion Pharmaceuticals (ACHN) crashed 60% last week, after the company stated that the FDA maintained its clinical hold on its leading hepatitis C (HCV) drug, sovaprevir, which has been on hold for more than three months due to fears that it could cause liver damage. That news devastated shareholders, who had hoped that<br /><a class="moretag" href="http://www.investorguide.com/article/14088/achillion-pharmaceuticals-achn-gets-wiped-out-after-fda-maintains-hold-on-its-lead-drug-sod/">Read the full article...</a></p><p>Read the rest of <a href="http://www.investorguide.com/article/14088/achillion-pharmaceuticals-achn-gets-wiped-out-after-fda-maintains-hold-on-its-lead-drug-sod/">Achillion Pharmaceuticals (ACHN) Gets Wiped Out After FDA Maintains Hold On Its Lead Drug</a> at <a href="http://www.investorguide.com/article">InvestorGuide.com</a>.</p>]]></description>
		<wfw:commentRss>http://www.investorguide.com/article/14088/achillion-pharmaceuticals-achn-gets-wiped-out-after-fda-maintains-hold-on-its-lead-drug-sod/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	    <image>
   http://www.investorguide.com/images/social/social-stock-1.jpg  	</image>
	</item>
		<item>
		<title>Gilead Sciences (GILD) Rallies After Ending a Late-Stage Trial Ahead of Schedule</title>
		<link>http://www.investorguide.com/article/14084/gilead-sciences-gild-rallies-after-ending-a-late-stage-trial-ahead-of-schedule-sod/</link>
		<comments>http://www.investorguide.com/article/14084/gilead-sciences-gild-rallies-after-ending-a-late-stage-trial-ahead-of-schedule-sod/#comments</comments>
		<pubDate>Mon, 14 Oct 2013 14:04:25 +0000</pubDate>
		<dc:creator>Leo Sun</dc:creator>
				<category><![CDATA[Market Commentary]]></category>
		<category><![CDATA[Stock of the Day]]></category>
		<category><![CDATA[IG Original]]></category>

		<guid isPermaLink="0">http://www.investorguide.com/article/?p=14084</guid>
		<description><![CDATA[<p>Shares of Gilead Sciences (GILD) surged last week, after the company announced that it had ended a late-stage clinical trial of its cancer drug idelalisib earlier than anticipated because it was confident that the treatment was working. Idelalisib is a new treatment for chronic lymphocytic leukemia (CLL) and indolent (slow growing) non-Hodgkin lymphoma (iNHL). Daily<br /><a class="moretag" href="http://www.investorguide.com/article/14084/gilead-sciences-gild-rallies-after-ending-a-late-stage-trial-ahead-of-schedule-sod/">Read the full article...</a></p><p>Read the rest of <a href="http://www.investorguide.com/article/14084/gilead-sciences-gild-rallies-after-ending-a-late-stage-trial-ahead-of-schedule-sod/">Gilead Sciences (GILD) Rallies After Ending a Late-Stage Trial Ahead of Schedule</a> at <a href="http://www.investorguide.com/article">InvestorGuide.com</a>.</p>]]></description>
		<wfw:commentRss>http://www.investorguide.com/article/14084/gilead-sciences-gild-rallies-after-ending-a-late-stage-trial-ahead-of-schedule-sod/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	    <image>
   http://www.investorguide.com/images/social/social-stock-2.jpg  	</image>
	</item>
		<item>
		<title>Microsoft (MSFT) Investors Revolt Against Chairman Bill Gates</title>
		<link>http://www.investorguide.com/article/14077/microsoft-msft-investors-revolt-against-chairman-bill-gates-sod/</link>
		<comments>http://www.investorguide.com/article/14077/microsoft-msft-investors-revolt-against-chairman-bill-gates-sod/#comments</comments>
		<pubDate>Fri, 11 Oct 2013 14:16:33 +0000</pubDate>
		<dc:creator>Leo Sun</dc:creator>
				<category><![CDATA[Stock of the Day]]></category>
		<category><![CDATA[IG Original]]></category>

		<guid isPermaLink="0">http://www.investorguide.com/article/?p=14077</guid>
		<description><![CDATA[<p>Microsoft (MSFT) shareholders recently started a revolt against chairman Bill Gates, who co-founded the company 38 years ago and is still widely regarded as the face of the company. Three of the top 20 investors in Microsoft, which together own 5% of the company, are pressuring the board to force Bill Gates to step down,<br /><a class="moretag" href="http://www.investorguide.com/article/14077/microsoft-msft-investors-revolt-against-chairman-bill-gates-sod/">Read the full article...</a></p><p>Read the rest of <a href="http://www.investorguide.com/article/14077/microsoft-msft-investors-revolt-against-chairman-bill-gates-sod/">Microsoft (MSFT) Investors Revolt Against Chairman Bill Gates</a> at <a href="http://www.investorguide.com/article">InvestorGuide.com</a>.</p>]]></description>
		<wfw:commentRss>http://www.investorguide.com/article/14077/microsoft-msft-investors-revolt-against-chairman-bill-gates-sod/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	    <image>
   http://www.investorguide.com/images/social/social-stock-2.jpg  	</image>
	</item>
		<item>
		<title>Amazon (AMZN) Faces Major Challenges in France</title>
		<link>http://www.investorguide.com/article/14074/amazon-amzn-faces-major-challenges-in-france-sod/</link>
		<comments>http://www.investorguide.com/article/14074/amazon-amzn-faces-major-challenges-in-france-sod/#comments</comments>
		<pubDate>Thu, 10 Oct 2013 14:01:03 +0000</pubDate>
		<dc:creator>Leo Sun</dc:creator>
				<category><![CDATA[Stock of the Day]]></category>
		<category><![CDATA[IG Original]]></category>

		<guid isPermaLink="0">http://www.investorguide.com/article/?p=14074</guid>
		<description><![CDATA[<p>E-commerce giant Amazon (AMZN) was hit last week in France, after French lawmakers aimed to protect local bookshops from online booksellers. The newly passed law, which still needs to clear the Senate, bars online booksellers from offering free delivery to customers, as well as capping discounts at a maximum of 5%. The law reflects other<br /><a class="moretag" href="http://www.investorguide.com/article/14074/amazon-amzn-faces-major-challenges-in-france-sod/">Read the full article...</a></p><p>Read the rest of <a href="http://www.investorguide.com/article/14074/amazon-amzn-faces-major-challenges-in-france-sod/">Amazon (AMZN) Faces Major Challenges in France</a> at <a href="http://www.investorguide.com/article">InvestorGuide.com</a>.</p>]]></description>
		<wfw:commentRss>http://www.investorguide.com/article/14074/amazon-amzn-faces-major-challenges-in-france-sod/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	    <image>
   http://www.investorguide.com/images/social/social-stock-1.jpg  	</image>
	</item>
		<item>
		<title>JC Penney (JCP) Improves Outlook</title>
		<link>http://www.investorguide.com/article/14068/jc-penney-jcp-improves-outlook-sod/</link>
		<comments>http://www.investorguide.com/article/14068/jc-penney-jcp-improves-outlook-sod/#comments</comments>
		<pubDate>Wed, 09 Oct 2013 15:51:06 +0000</pubDate>
		<dc:creator>Jay Hawk</dc:creator>
				<category><![CDATA[Stock of the Day]]></category>
		<category><![CDATA[IG Original]]></category>

		<guid isPermaLink="0">http://www.investorguide.com/article/?p=14068</guid>
		<description><![CDATA[<p>Shares of JC Penney Company Inc. (JCP) closed up +0.06 or +0.78 percent to $7.77 per share on Tuesday, after having traded as high as $8.24 intraday. The stock was affected by the company releasing some financial information ahead of its fiscal third quarter earnings results to be released next month. JC Penney stock has<br /><a class="moretag" href="http://www.investorguide.com/article/14068/jc-penney-jcp-improves-outlook-sod/">Read the full article...</a></p><p>Read the rest of <a href="http://www.investorguide.com/article/14068/jc-penney-jcp-improves-outlook-sod/">JC Penney (JCP) Improves Outlook</a> at <a href="http://www.investorguide.com/article">InvestorGuide.com</a>.</p>]]></description>
		<wfw:commentRss>http://www.investorguide.com/article/14068/jc-penney-jcp-improves-outlook-sod/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	    <image>
   http://www.investorguide.com/images/social/social-stock-3.jpg  	</image>
	</item>
		<item>
		<title>Tesla (TSLA) Stock Bursts Into Flames</title>
		<link>http://www.investorguide.com/article/14061/tesla-tsla-stock-bursts-into-flames-sod/</link>
		<comments>http://www.investorguide.com/article/14061/tesla-tsla-stock-bursts-into-flames-sod/#comments</comments>
		<pubDate>Tue, 08 Oct 2013 14:19:55 +0000</pubDate>
		<dc:creator>Leo Sun</dc:creator>
				<category><![CDATA[Stock of the Day]]></category>
		<category><![CDATA[IG Original]]></category>

		<guid isPermaLink="0">http://www.investorguide.com/article/?guid=d17b4397959d8dd17c7c049eb13be014</guid>
		<description><![CDATA[<p>		Shares of electric automaker Tesla Motors (TSLA) tumbled last week, after video footage of a fire engulfing its top-selling Model S started to circulate on the Internet, raising safety concerns regarding its lithium ion battery packs. Despite the ne...</p><p>Read the rest of <a href="http://www.investorguide.com/article/14061/tesla-tsla-stock-bursts-into-flames-sod/">Tesla (TSLA) Stock Bursts Into Flames</a> at <a href="http://www.investorguide.com/article">InvestorGuide.com</a>.</p>]]></description>
		<wfw:commentRss>http://www.investorguide.com/article/14061/tesla-tsla-stock-bursts-into-flames-sod/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	    <image>
   http://www.investorguide.com/images/social/social-stock-2.jpg  	</image>
	</item>
		<item>
		<title>Bill Ackman Concedes Defeat On Herbalife (HLF)</title>
		<link>http://www.investorguide.com/article/14055/bill-ackman-concedes-defeat-on-herbalife-hlf-sod/</link>
		<comments>http://www.investorguide.com/article/14055/bill-ackman-concedes-defeat-on-herbalife-hlf-sod/#comments</comments>
		<pubDate>Mon, 07 Oct 2013 14:18:05 +0000</pubDate>
		<dc:creator>Leo Sun</dc:creator>
				<category><![CDATA[Stock of the Day]]></category>
		<category><![CDATA[IG Original]]></category>

		<guid isPermaLink="0">http://www.investorguide.com/article/?guid=61d7ca07b1edc8a12098cef2147a6897</guid>
		<description><![CDATA[<p>		It's been a rough year for hedge fund manager Bill Ackman. His decision to short Herbalife (HLF) blew up in his face after activist investor Carl Icahn took him down, and his bet on a J.C. Penney (JCP) turnaround met with similar failure. During tha...</p><p>Read the rest of <a href="http://www.investorguide.com/article/14055/bill-ackman-concedes-defeat-on-herbalife-hlf-sod/">Bill Ackman Concedes Defeat On Herbalife (HLF)</a> at <a href="http://www.investorguide.com/article">InvestorGuide.com</a>.</p>]]></description>
		<wfw:commentRss>http://www.investorguide.com/article/14055/bill-ackman-concedes-defeat-on-herbalife-hlf-sod/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	    <image>
   http://www.investorguide.com/images/social/social-stock-1.jpg  	</image>
	</item>
		<item>
		<title>Nike (NKE) Sprints Past Earnings Estimates</title>
		<link>http://www.investorguide.com/article/14050/nike-nke-sprints-past-earnings-estimates-sod/</link>
		<comments>http://www.investorguide.com/article/14050/nike-nke-sprints-past-earnings-estimates-sod/#comments</comments>
		<pubDate>Fri, 04 Oct 2013 14:11:26 +0000</pubDate>
		<dc:creator>Leo Sun</dc:creator>
				<category><![CDATA[Stock of the Day]]></category>
		<category><![CDATA[IG Original]]></category>

		<guid isPermaLink="0">http://www.investorguide.com/article/?guid=d5949d3e01414929c7dc103107145114</guid>
		<description><![CDATA[<p>		Nike (NKE) blew away Wall Street last week, after reporting earnings that topped analyst estimates by a wider margin. The athletic footwear and apparel maker's diluted earnings per share rose 37% to $0.86 per share, while revenue climbed 8% to $7.0 ...</p><p>Read the rest of <a href="http://www.investorguide.com/article/14050/nike-nke-sprints-past-earnings-estimates-sod/">Nike (NKE) Sprints Past Earnings Estimates</a> at <a href="http://www.investorguide.com/article">InvestorGuide.com</a>.</p>]]></description>
		<wfw:commentRss>http://www.investorguide.com/article/14050/nike-nke-sprints-past-earnings-estimates-sod/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	    <image>
   http://www.investorguide.com/images/social/social-stock-1.jpg  	</image>
	</item>
	</channel>
</rss>
